Navigation Links
Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies.

In a chapter of the text that reviews immunotoxins, Susanna Rybak, Ph.D. summarizes preclinical research indicating that the specificity and potency of ONCONASE improves in a number of tumor models, including non-Hodgkin's lymphoma, when it is conjugated with various antibodies. Dr. Rybak also reviews evidence that implies that ONCONASE may also be effectively targeted to tumors as a conjugate with non-internalizing antibodies, as compared with the internalizing antibodies required by standard plant and bacterial toxins.

"Antibody-targeted ONCONASE is the most potent targeted ribonuclease (RNase) that I have studied," Dr. Rybak said. "While immunotoxins have entered the arsenal of anti-cancer drugs, there have been problems with their clinical use. ONCONASE's excellent performance in preclinical studies makes it a very promising candidate for testing in the clinic."

"It is a great honor to be included in this important industry reference book," added Kuslima Shogen, Alfacell's chairman and chief executive officer. "This work is further evidence of the opportunity that exists for us to build a significant ONCONASE franchise, as a single agent, in combination therapy or as a payload in antibody conjugates. ONCONASE has the potential to be an effective, highly targeted agent for the treatment of various cancers beyond mesothelioma."

For more than 25 years, Dr. Rybak's research has centered on the biology of RNases, antibody engineering and drug targeting. Her laboratory at the National Cancer Institute (NCI) developed the groundwork for RNase-based therapeutics for NHL and breast cancer. Dr. Rybak, who is a member of Alfac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
11. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:7/27/2015)... KONG , July 27, 2015 Bloomage ... 00963.HK) announces a strategic cooperation with the South Korean ... establish a joint venture Medybloom to develop and promote ... China . Medytox, the ... Korea, and is also the fourth company in the ...
(Date:7/27/2015)... 27, 2015  Cardica, Inc. (Nasdaq: CRDC ) today ... fourth quarter ended June 30, 2015, on Thursday, August 6, ... conference call at 4:30 p.m. Eastern Time to discuss the ... Conference Call Details To access the live ... Time via phone, please dial 877-703-6106 from the ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7lz2fk/intraoperative ) has announced the ... (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) , by Geography ... 2019" report to their offering. ... $2.1 Billion by 2019 from $1.8 Billion in 2014, ... The intraoperative imaging market is divided ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
... Wash., Feb. 21, 2011 Royal Philips Electronics NV ... MSFT ) today announced the companies will collaborate ... to build and understand the complete clinical context of ... commitment to work together to connect technologies that will ...
... Medical, Inc. (Nasdaq: NXTM ), a leading ... recent independent study which reports that home hemodialysis with ... carbon footprint of therapy conducted with traditional in-center hemodialysis ... delivering superior clinical results is a core competency of ...
Cached Medicine Technology:Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 2Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 3Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 2Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 3
(Date:7/28/2015)... , ... July 28, 2015 , ... Intellitec Solutions has ... Today’s annual ranking of Value Added Resellers of ERP Software is a look at ... presented with. This honor represents the second such award in 2015 for Intellitec Solutions, ...
(Date:7/28/2015)... ... July 28, 2015 , ... Carol McFarland, ... with discussion and demonstration of specific rehabilitation exercises and treatment protocols in the ... surgical process with an extensive interview conducted by Carol with a board certified ...
(Date:7/28/2015)... Cupertino, CA (PRWEB) , ... July 28, 2015 ... ... now offering complimentary consultations for Invisalign. Invisalign is a revolutionary orthodontic treatment that ... a combination of Dr. Mozafari’s expertise and 3D computer imaging technology. You wear ...
(Date:7/27/2015)... ... July 28, 2015 , ... Almost a year ago, the ... behavioral health counseling for persons who are obese and those who are overweight with ... , That mandate will affect any commercial health plan with a program year start ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific ... with smaller regional brain volumes that may be early indicators of Alzheimer’s disease ... “We already know that vascular risk factors damage the brain and can result ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3
... the fifth most common complaint seen in the medical office ... considered a disease of the lungs, organs and tissues of ... tract, or even psychiatric in nature. The common treatments are ... ,A seizure drug may be the answer to quieting ...
... occur each year in the United States. Investigators have been tracking ... years to see how various factors might impact their risk for ... of dementia in those with and without a history of stroke.About ... compared to just 11 percent of those who didn’t have a ...
... improve lifestyle habits may not lower blood pressure in ... ,Researchers investigated whether simple interventions, such as ... intake, and advice for a healthier diet, had more ... 300 patients without an established history of high blood ...
... that about 1 million women in the United ... may encounter // a wide-range of problems while ... that many women find their seizures change in ... menopause. Researchers say hormonal changes may be responsible ...
... diseases such as flu, measles, whooping cough and other ... from coming back. // ,Non-Hodgkin's lymphoma is ... comes back, even after chemotherapy and eventually most of ... their lymphoma. ,The vaccine is made from a ...
... epidemic with the highest incidence rate and a high fatality ... and 299 deaths in a ,population of 6.7 million. ... SARS in Hong Kong. It seems the air may be ... care professionals must take the potential for airborne spread of ...
Cached Medicine News:
Honing compound for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard vice clamp, can be fitted instead of Quick Realease Cassette...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
Medicine Products: